Hardman Johnston Global Advisors LLC raised its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 0.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 86,512 shares of the medical instruments supplier’s stock after purchasing an additional 400 shares during the period. Hardman Johnston Global Advisors LLC’s holdings in Becton, Dickinson and were worth $16,952,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of BDX. Mawer Investment Management Ltd. lifted its holdings in Becton, Dickinson and by 1.3% during the first quarter. Mawer Investment Management Ltd. now owns 1,768,539 shares of the medical instruments supplier’s stock valued at $324,418,000 after purchasing an additional 22,563 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in Becton, Dickinson and by 6.5% during the first quarter. JPMorgan Chase & Co. now owns 3,967,843 shares of the medical instruments supplier’s stock valued at $727,863,000 after purchasing an additional 242,081 shares in the last quarter. YHB Investment Advisors Inc. lifted its holdings in Becton, Dickinson and by 95.6% during the first quarter. YHB Investment Advisors Inc. now owns 20,289 shares of the medical instruments supplier’s stock valued at $3,793,000 after purchasing an additional 9,915 shares in the last quarter. KBC Group NV lifted its holdings in Becton, Dickinson and by 7.0% during the first quarter. KBC Group NV now owns 42,988 shares of the medical instruments supplier’s stock valued at $7,886,000 after purchasing an additional 2,816 shares in the last quarter. Finally, Prudential Financial Inc. lifted its holdings in Becton, Dickinson and by 34.0% during the first quarter. Prudential Financial Inc. now owns 930,445 shares of the medical instruments supplier’s stock valued at $170,681,000 after purchasing an additional 236,280 shares in the last quarter. 86.71% of the stock is currently owned by institutional investors and hedge funds.

In related news, insider Gary M. Cohen sold 15,512 shares of Becton, Dickinson and stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $203.77, for a total value of $3,160,880.24. Following the completion of the transaction, the insider now owns 95,781 shares in the company, valued at $19,517,294.37. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Ribo Alberto Mas sold 7,463 shares of Becton, Dickinson and stock in a transaction that occurred on Monday, August 14th. The shares were sold at an average price of $201.41, for a total transaction of $1,503,122.83. Following the completion of the transaction, the executive vice president now owns 29,323 shares of the company’s stock, valued at approximately $5,905,945.43. The disclosure for this sale can be found here. Insiders sold 69,933 shares of company stock valued at $14,063,953 in the last 90 days. Company insiders own 1.40% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Hardman Johnston Global Advisors LLC Has $16.95 Million Position in Becton, Dickinson and Company (BDX)” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/11/08/hardman-johnston-global-advisors-llc-has-16-95-million-position-in-becton-dickinson-and-company-bdx.html.

Shares of Becton, Dickinson and Company (BDX) opened at $221.27 on Wednesday. Becton, Dickinson and Company has a 12-month low of $161.29 and a 12-month high of $225.23. The firm has a market cap of $50,564.94, a PE ratio of 23.41, a price-to-earnings-growth ratio of 1.74 and a beta of 1.04. The company has a debt-to-equity ratio of 1.48, a quick ratio of 5.01 and a current ratio of 5.56.

Becton, Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share for the quarter, beating analysts’ consensus estimates of $2.37 by $0.03. The firm had revenue of $3.17 billion during the quarter, compared to analysts’ expectations of $3.14 billion. Becton, Dickinson and had a net margin of 8.52% and a return on equity of 22.51%. The business’s quarterly revenue was down 2.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.12 earnings per share. equities research analysts anticipate that Becton, Dickinson and Company will post 10.6 EPS for the current year.

BDX has been the topic of several research reports. Wells Fargo & Company reissued a “positive” rating and issued a $235.00 price target (up from $225.00) on shares of Becton, Dickinson and in a research note on Tuesday, October 24th. They noted that the move was a valuation call. BidaskClub downgraded shares of Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Piper Jaffray Companies reissued a “buy” rating and issued a $213.00 price target on shares of Becton, Dickinson and in a research note on Tuesday, September 12th. Morgan Stanley raised their price target on shares of Becton, Dickinson and from $205.00 to $245.00 and gave the stock an “equal weight” rating in a research note on Friday, November 3rd. Finally, Bank of America Corporation reissued a “buy” rating and issued a $225.00 price target (up from $200.00) on shares of Becton, Dickinson and in a research note on Friday, July 21st. Five research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. Becton, Dickinson and currently has an average rating of “Buy” and a consensus target price of $213.47.

Becton, Dickinson and Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related stocks with our FREE daily email newsletter.